NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a ...

Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So should Keros Therapeutics (NASDAQ:KROS) shareholders be worried about its cash burn?

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to ...

Fintel reports that on January 17, 2025, Wedbush downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from ...

Fintel reports that on January 21, 2025, Cantor Fitzgerald downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) ...

Keros Therapeutics (NASDAQ:KROS – Get Free Report) had its target price cut by equities research analysts at Oppenheimer from ...

Keros Therapeutics (NASDAQ:KROS) traded higher on Tuesday after the company announced that its previously announced licensing agreement with Takeda (TAK) for its lead asset elritercept took effect ...

Shares of Keros Therapeutics KROS, a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing ...

On Tuesday, Keros Therapeutics (NASDAQ:KROS) faced a downgrade in stock rating from Buy to Neutral by Cantor Fitzgerald. The stock, which has declined nearly 80% over the past year according to ...

Keros Therapeutics (KROS) stock rises as a licensing deal with Takeda (TAK) begins. However, Cantor Fitzgerald downgrades, citing a trial setback. Read more here.